QV Bioelectronics Ltd.

QV Bioelectronics is developing an implanted electrotherapy device to increase the life expectancy of patients with glioblastoma, the most common primary brain cancer. Electrotherapy is an approved treatment that has been able to extend patient survival, however with only cumbersome and heavy externally-applied devices. QV’s device is implanted during tumor removal surgery to deliver the electrical fields continuously and focally to the site of the cancer cells; delivering improved survival outcomes with better patient quality of life.